by Alan McCann | Feb 9, 2021 | Uncategorized
Multi-site clinical study to evaluate BioBridge®as prophylactic treatment for at-risk patients UNION CITY, Calif.–(BUSINESS WIRE)–Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the...
by Alan McCann | Sep 14, 2020 | Uncategorized
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
by Alan McCann | Jun 3, 2020 | Uncategorized
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.–(BUSINESS WIRE)–Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has...
by Alan McCann | Jan 22, 2019 | Uncategorized
Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing...
by Alan McCann | Jan 12, 2019 | Uncategorized
Fibralign received Certification Notification on January 21, 2019 from DEKRA Certification B. V. that the Company’s management system meets the requirements of EN ISO 13486:2016. This internationally agreed standard sets out the requirements for a quality...
by Alan McCann | Feb 17, 2018 | Uncategorized
Fibralign received Certification Notification on February 18, 2018 from notifying body DEKRA Certification B. V. that it’s management system meets the requirements of EN ISO 13486:2016:2012 + AC:2012. The scope of the certification is for the design,...
